AstraZeneca Pharma India Limited — Important, 06-03-2025: Updates

AstraZeneca Pharma India Limited has secured permission from the Central Drugs Standard Control Organisation to import Sodium Zirconium Cyclosilicate powder for oral suspension (5 g and 10 g), branded as Lokelma. This drug is indicated for treating hyperkalaemia in adult patients. The approval positions the company to launch Lokelma in India, contingent upon obtaining any necessary further statutory approvals. This development could enhance AstraZeneca's product portfolio and market presence, particularly in the therapeutic area of hyperkalaemia, offering a positive outlook for future revenue growth. Investors should watch closely for the launch timeline and market reception.